Arkolith/Insider Trading/MREO/Form 4

Fox Christine Ann

Chief Financial OfficerMereo BioPharma Group plc (MREO) · full profile →Form 4 · filed Sep 16, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$122K
Net Open-Market Flow
-$122K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 13, 2024Sell(S)19K$4.22$81K89K
Sep 12, 2024Sell(S)9K$4.47$41K108K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-106970) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML